logo
Persuasion Can't Revalidate Your Customer's Assay

Strivenn Thinking

Pull up a seat at our
digital campfire
where story, strategy,
and AI spark
new possibilities
for sharper brands
and smarter teams.

Customer Insight

Persuasion Can't Revalidate Your Customer's Assay

Securitas leaned on a column

Securitas was the Roman goddess of security and stability. Her name literally translates to se + cura, "without care." Before she appeared on coins, securitas was simply the Latin word for peace of mind.



From the reign of Nero onward, Roman emperors put her on their coins. She is rarely shown doing anything. She stands or sits at ease, usually leaning on a column. Her relaxed pose depends on that column. Take it away and she would fall over.



As Product Managers (PMs) in life science tools, we try to give buyers that same calm, and we mostly do it with words describing the specifications. Words won't hold up a lab head who is about to bet three years of data on a new kit. She needs a column of her own: proof that her new data will match her old data, and a safe way to switch. Building that column is a product decision, and most product requirements documents (PRDs) skip it. They specify what the buyer gains in detail and say nothing about what she stands to lose.



Your buyer is convinced and still won't switch

A pharma biomarker lab has run the same cytokine ELISA for three years. Your new kit has a lower limit of detection and a wider dynamic range. The lab head agrees it is better. Then she asks the question your product specification sheet doesn't answer: "Will my new numbers line up with three years of banked study data?" If nobody can answer that before purchase, the safest choice is the incumbent kit she already runs.



Harvard's John Gourville calls this the 9x effect. Buyers weigh what they would lose by switching about three times more heavily than what they would gain, and the companies selling to them overvalue their new product by about three times. That leaves a nine-to-one gap between what the seller thinks the product is worth and what the buyer needs before switching. For our lab head, the gain is a lower limit of detection. The loss is three years of data she may no longer be able to compare. That makes her own archive the competitor you actually have to beat.



Her hesitation points to a different gap from the one I described in You Called It a Launch. That launch lacked the proof to get buyers evaluating. This lab head has already finished evaluating. What's missing is concordance data showing how the new kit's results compare with her current kit, and a limit on what saying yes will cost her. Once the product is on the market, filling that gap becomes a product care project, and her purchase waits until it is done.



Where persuasion stops

Hamid Ghanadan has written the playbook for persuading scientists, most recently in Not Buying It. His work explains how technical buyers process product claims and why facts alone rarely move them. Persuasion still has a limit. A persuasive pitch can convince our lab head that the new kit performs better, but it can't produce concordance data from her banked samples or rewrite her validated standard operating procedure (SOP). Revalidation also burns staff hours, often enough to erase a competitor's price advantage in the first month.



Those are product gaps, and product gaps belong in the PRD.



The verification report proves the kit meets its specification. It says nothing about whether your customer's historical data still means anything after the switch. That is a validation question, asked in the customer's context, and pharma labs already have a name for it. ICH M10 calls it cross validation, and the FDA's 2025 biomarker validation guidance points biomarker labs to M10 as their starting point. On the vendor side, the question usually gets answered by a field application scientist (FAS) working months after the deal has already stalled.



Buyers already weigh validation evidence about as heavily as brand experience, according to BioInfo's survey of antibody buyers, and I have written before about getting that evidence out of internal reports. A bridging study adds the one piece of evidence those reports never contain: what happens to her data.



Three columns every launch needs

These columns answer a budget question: what should you build before launch so that buyers who already like the kit actually place an order? Skip them and your pipeline fills with "still evaluating" accounts, while first-year moving annual total (MAT) falls short of the business case. Each column answers one question a cautious or skeptical buyer asks before switching. Treat each one like a performance spec, with a switching-risk criterion checked at the Launch Gate.



  Equivalence evidence Transfer package Fallback commitment
Buyer's question Will my new data match my old data? How much work is the switch? What happens if it fails?
PRD item Bridging study against the incumbent kit your target accounts already run, producing concordance data with correlation and conversion guidance SOP template, plate-map conversion guide, validation protocol template, training module, installation, operational and performance qualification (IQ/OQ/PQ) support for instruments Defined parallel-run window, kit credit terms, named escalation owner
Owner Applications Development, with FAS support for customers Applications and technical support PM and commercial lead
Switching-risk criterion (illustrative) On the same 200 banked samples, new-kit results fall within ±20% of the incumbent's, or convert with a published factor Customer revalidation in 5 full-time equivalent (FTE) days or fewer 60-day parallel run at no kit cost

What the lab head gets:



  • Her three years of data still count.
  • She knows how many weeks the switch costs.
  • If the kit fails, she isn't the one left explaining it.

Finance will ask what this costs before launch. Answer with the revenue already in your business case. Here is an illustrative case. If the forecast assumes 40 pharma accounts at $60,000 a year in kit orders, and half of them hesitate because nobody can show how the new results compare with the old ones, $1.2 million of year-one revenue is at risk. A bridging study on 200 banked serum samples across three sites may cost about $85,000. If the study wins over just two of those hesitant accounts, their $120,000 a year in kit orders more than pays for the bridging study. For an instrument, run the same math on placed systems plus their consumable pull-through.



Before: the bridging study is an FAS side project that starts after a deal stalls.



After: it is a PRD requirement with its own budget line and Gate date, and the report is ready on launch day.



Run the column test before your Launch Gate

  1. Open your last PRD and count two things: the specs that describe what the buyer gains, and the specs that describe what she stands to lose. In most PRDs I have seen, the second count is zero. That zero is the 9x gap, written down and signed off at the Gate. In Value Proposition Canvas terms, you filled in every gain creator and left the pain relievers blank.
  2. Write down the three questions your most cautious buyer will ask before switching. Fine-tune these questions with a grounded synthetic customer, then get the answers from a real lab head.
  3. For each question, name the document your lab head could forward to her study director today, like a bridging report. If all you have is a slide deck or "sales will handle it," that column is missing from your launch.
  4. Add each missing column to the PRD. When finance pushes back, show the year-one revenue your business case puts at risk without them.

Your toughest competitor is her archive

On Roman coins, Securitas is never shown persuading anyone. She leans on her column, and the column holds her weight. Your buyer needs something that solid before she bets her data set on you, and it has to be in the PRD long before anyone writes the launch deck.



The launches I have seen stall didn't lose to a rival kit. They lost to the customer's own archive, and nobody had written that archive into the PRD as a competitor.

 

FAQs

Our launch date is fixed and the bridging study won't finish in time. What now?
R&D says concordance data is marketing's job. Who owns it?
What if the bridging study shows our kit doesn't match the incumbent?


Are you Strivenn to Succeed?

Book your growth consultation with the marketing doctor today